Alec Nathanson Flyer

USPTO Granted Patents = 13 (Patent Applications = 6)

EPO Patents = 3 (Patent Applications = 8)

Average Co-Inventor Count = 6.7

ph-index = 2

Forward Citations = 19(Granted Patents)

Location History:

Charlestown, MA (US) (2021)
Boston, MA (US) (2017 - 2022)
Cambridge, MA (US) (2014 - 2023)

Company Filing History:

Selux Diagnostics, Inc.

Years Active: 2014-2025

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12209144 - Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders (2025-01-28),

2. 11813306 - Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders (2023-11-14),

3. 11427586 - 1,2,4-oxadiazole derivatives as liver X receptor agonists (2022-08-30),

4. 11026993 - Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders (2021-06-08),

5. 10982254 - Methods for rapid antimicrobial susceptibility testing (2021-04-20),

6. 10501772 - Methods for rapid antimicrobial susceptibility testing (2019-12-10),

7. 10202400 - Cortistatin analogues and syntheses thereof (2019-02-12),

8. 10048269 - Assay methods involving dissociable nanoparticles (2018-08-14),

9. 9834808 - Methods for rapid antibiotic susceptibility testing (2017-12-05),

10. 9714255 - Cortistatin analogues and syntheses thereof (2017-07-25),

11. 9505755 - Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5A receptor modulators (2016-11-29),

12. 9127019 - Cortistatin analogues and synthesis thereof (2015-09-08),

13. 8846656 - Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators (2014-09-30),

Title: Alec Nathanson Flyer: Innovator in Metabolic Disorder Treatments

Introduction

Alec Nathanson Flyer is a prominent inventor based in Cambridge, MA, known for his significant contributions to the field of metabolic disorders. With a total of 13 patents to his name, he has made remarkable strides in developing innovative treatments that target lipid metabolism and related diseases.

Latest Patents

Flyer's latest patents include groundbreaking work on cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. These inhibitors are crucial for the treatment of metabolic disorders, particularly in managing lipid metabolism. His disclosures detail the use of cyclic tetramer compounds as PCSK9 inhibitors, which are beneficial in treating cholesterol lipid metabolism and other diseases influenced by PCSK9. The formulations described include various forms such as pharmaceutically acceptable salts, hydrates, and prodrugs, showcasing the versatility and potential of his inventions.

Career Highlights

Throughout his career, Alec Nathanson Flyer has worked with notable companies such as Novartis AG and Selux Diagnostics, Inc. His experience in these organizations has allowed him to collaborate with leading experts in the field, further enhancing his innovative capabilities.

Collaborations

Flyer has collaborated with esteemed colleagues, including Eric D. Stern and Aleksandar Vacic. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Alec Nathanson Flyer stands out as a key figure in the innovation of treatments for metabolic disorders. His extensive patent portfolio and collaborations with industry leaders underscore his commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.